MPOXED

New findings reported in Nature provide rare molecular evidence of direct mpox transmission from a rope squirrel to wild sooty mangabeys in Côte d’Ivoire. The work strengthens long-held suspicions that African rodents serve as reservoirs, but it also sharpens concern about zoonotic spillover. Where wildlife is hunted, traded, or consumed, ecological interfaces become epidemiologic fault lines. Understanding these transmission pathways is not academic. It is central to preventing future outbreaks that begin in forests and end in cities.

New research presented at IDWeek underscores that the intersection of HIV and mpox risk is shaped as much by access to care as by immunology. Data from New York City suggest that low CD4+ counts, untreated HIV, and coexisting infections such as syphilis were stronger predictors of severe mpox than viral load alone. Qualitative findings further reveal that stigma, provider uncertainty, and fear delayed care. Mpox severity among people with HIV reflects structural vulnerabilities that demand both clinical vigilance and equitable access to sustained HIV care.

The 2022 mpox outbreak exposed uneven readiness across U.S. health systems. Survey data presented at IDWeek reveal that testing access, delayed results, and inconsistent communication were the most significant institutional challenges. Even large academic centers struggled when turnaround times stretched to a week, undermining contact tracing and containment. While many hospitals adapted lessons from COVID-19 to mobilize faster, experts such as Boghuma Titanji warn that continued erosion of public health infrastructure may leave systems more vulnerable today. Preparedness gains are real but fragile.

A rigorous trial published in The New England Journal of Medicine delivers a sobering conclusion: tecovirimat offers no measurable benefit over placebo for clade II mpox. The STOMP study found no significant differences in time to clinical resolution, pain reduction, or viral DNA clearance. For a drug widely deployed under emergency conditions and approved for smallpox under the Animal Rule, the findings underscore a critical lesson. Assumptions must yield to randomized evidence. The search for safe and effective mpox therapeutics must continue with scientific discipline and urgency.

The confirmation of a recombinant mpox strain in the United Kingdom and India is a reminder that viral evolution does not pause when case counts decline. According to the World Health Organization, the strain combines genetic elements of clades Ib and IIb and demonstrates replication potential. While only two cases have been detected and illness was not severe, recombination signals ongoing viral opportunity. Surveillance systems must rely on genomic sequencing, not clade-specific PCR alone, to detect such shifts. Vigilance, not alarm, is the appropriate response.

Mpox recovery is proving far less straightforward than once assumed. Findings published in Annals of Internal Medicine show that more than half of patients continued to experience physical or functional sequelae up to 18 months after acute infection. Persistent scarring and ongoing anorectal or urinary dysfunction were common, even when psychosocial symptoms resembled those of at-risk but uninfected individuals. These data reinforce that mpox is not always a short-lived illness. Long-term follow-up and integrated care should be considered routine components of mpox management, not exceptional measures.

Africa’s decision to lift mpox as a Public Health Emergency of Continental Security reflects a hard-earned shift from crisis response to sustained control. Under the leadership of Africa CDC, coordinated action, regional solidarity, and international partnership drove sharp declines in cases and fatalities while expanding surveillance, laboratory capacity, vaccination, and research. This milestone should not be misread as closure. Mpox remains endemic in parts of the continent, and the transition now demands vigilance, investment, and country-led ownership to consolidate gains and prevent resurgence.

Mpox has been widely framed as an acute illness, but new evidence challenges that narrative. Research published in Annals of Internal Medicine shows that for many patients, recovery does not end when lesions heal. Persistent scarring, functional complications, and social consequences including stigma and job loss continue long after infection. As clade IIb mpox circulates at low levels and clade I resurges elsewhere, public health responses must expand beyond containment. Long-term follow-up, rehabilitation, and psychosocial support should be treated as integral components of mpox care, not afterthoughts.

New research suggests mpox is both quieter and more persistent than surveillance systems assume. Evidence published in Nature Communications points to silent circulation in Nigeria, where immune markers reveal recent mpox exposure without recognized illness. At the same time, findings in Annals of Internal Medicine show that more than half of patients experience lasting physical or psychosocial effects long after diagnosis. Together, these studies challenge symptom-based surveillance and short-term care models. Mpox control must account for unseen transmission and long-term consequences, not just reported cases.